全球领先疫苗,39支疫苗进入3期实验,10月13日,德国法国放弃两款mRNA疫苗,转为研发新一代疫苗和加强剂。中国两款疫苗进入第三期试验。

老人自然要更加小心。每年流感也会死不少老人。
不过身体不健康就活不长,人老了自然要死。这是自然规律
不论化多少多钱建医院,也只能对人民健康做有限帮助。而且社会资源是有限的。
如果重症率死亡率降到历史上的相对低位,生活自然要恢复到相对正常。
有些东西你再担心,也是改变不了的。改变不了的,你担心有啥用?


又扯上身体健康了,如果大家身体都健康的话安省还花那么多钱建医院干嘛?是的身体暂时健康的人可能不用担心, 可那些身体不健康的呢? 看看那些老人。
 
1601319126211.png

全球领先冲刺处于三期的10支疫苗,其中俄国一支已获批准,但是跳过了二期试验。美国Novavax Protein subunit疫苗新近进入3期试验。

加拿大最领先的一只完成1期试验。
Medicago Virus-like particlesCompleteComplete

https://newsinteractives.cbc.ca/coronavirusvaccinetracker/#non-replicating-viral-vector
 
15 hr 57 min ago
AstraZeneca vaccine trial still on hold in US but FDA’s Hahn won’t reveal why; it’s "confidential”
From CNN Health’s Shelby Lin Erdman and Jen Christensen


A general view of AstraZeneca on August 19, in Sydney, Australia.

A general view of AstraZeneca on August 19, in Sydney, Australia. Lisa Maree Williams/Getty Images

Drugmaker AstraZeneca’s Covid-19 vaccine trial in the United States is still on hold after a participant developed a serious illness, but the Food and Drug Administration commissioner won’t say why.

At the US Pharma and Biotech Summit hosted by the Financial Times Wednesday, US FDA Commissioner Dr. Stephen Hahn was asked why the trial was still on pause in the US, even though it has resumed in Europe. Hahn said he couldn’t answer.
“I can’t speak to confidential commercial information and this summit knows that all too well,” he said.
“Our agency career officials in general take the issue of serious safety very seriously, the protection of the American people, very seriously ... We will look at any and all data, and we will make a decision when we have the data available to us regarding any issue, whether it's safety or effectiveness."
Hahn said he could not talk about a “specific issue” that may involve the AstraZeneca trial.
“What I can tell you is that FDA is on the job with respect to looking at all safety and efficacy issues on all medical products,” he said.
An AstraZeneca spokesperson told CNN earlier that regulators in Britain, Brazil and South Africa had all decided to resume the trials. “We are continuing to work with the FDA to facilitate review of the information needed to make a decision regarding resumption of the US trial,” the spokesperson said.
“Regulators in each individual country determine when trials can start and they do this in their own time frame.”
 
15 hr 57 min ago
AstraZeneca vaccine trial still on hold in US but FDA’s Hahn won’t reveal why; it’s "confidential”
From CNN Health’s Shelby Lin Erdman and Jen Christensen


A general view of AstraZeneca on August 19, in Sydney, Australia.

A general view of AstraZeneca on August 19, in Sydney, Australia. Lisa Maree Williams/Getty Images

Drugmaker AstraZeneca’s Covid-19 vaccine trial in the United States is still on hold after a participant developed a serious illness, but the Food and Drug Administration commissioner won’t say why.

At the US Pharma and Biotech Summit hosted by the Financial Times Wednesday, US FDA Commissioner Dr. Stephen Hahn was asked why the trial was still on pause in the US, even though it has resumed in Europe. Hahn said he couldn’t answer.

Hahn said he could not talk about a “specific issue” that may involve the AstraZeneca trial.

An AstraZeneca spokesperson told CNN earlier that regulators in Britain, Brazil and South Africa had all decided to resume the trials. “We are continuing to work with the FDA to facilitate review of the information needed to make a decision regarding resumption of the US trial,” the spokesperson said.


美国又隐瞒。
中国的疫苗是中东做第三期。
中共不可能隐瞒可能的严重副作用。
 
Moderna's coronavirus vaccine won't be ready for widespread distribution until spring, CEO predicts

He reportedly predicted the vaccine wouldn't be available to the general public until sometime next spring

Just a day after President Trump said the nation was only “weeks away” from a coronavirus vaccine, the head of Moderna reportedly said his company will not be able to apply for authorization from the Food and Drug Administration (FDA) until late November at the earliest.

“November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA – assuming that the safety data is good, i.e. a vaccine is deemed safe,” Stephane Bancel, Moderna CEO, told the Financial Times on Wednesday.

He then predicted that the company would not be able to release the vaccine to the general public until sometime next spring.

“I think a late [first quarter], early [second quarter] approval, is a reasonable timeline, based on what we know from our vaccine,” he told the news outlet.

MODERNA SAYS CORONAVIRUS VACCINE BOOSTS IMMUNE SYSTEM RESPONSE IN OLDER ADULTS

The government has already struck a deal with Moderna for 100 million doses of the vaccine as part of Operation Warp Speed, with an option to buy an additional 400 million doses. Bancel has previously conceded that it will take more than one company to supply enough vaccines to combat the coronavirus.

The timeline regarding a coronavirus vaccine was a hot topic of debate on Tuesday night, as Trump and former Vice President Joe Biden sparred safety concerns of a rushed vaccine and over the White House’s response to the ongoing pandemic.

TRACES OF CORONAVIRUS FOUND IN LAKE SUPERIOR WATER, RESEARCHERS SAY

“I’ve spoken to the companies and we can have it a lot sooner… I’ve spoken to Pfizer, I’ve spoken to all of the people that you have to speak to – Moderna, Johnson & Johnson, and others,” Trump said during the debate, regarding a vaccine timeline. “They can go faster than that by a lot.”

On Tuesday, Moderna announced that its vaccine candidate, dubbed mRNA-1273, elicited immune responses in older adults from a Phase 1 study in levels comparable to those seen in younger adults.

“These interim Phase 1 data suggests that mRNA-1273, our vaccine candidate for the prevention of COVID-19, can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults,” Dr. Tal Zaks, chief medical officer of Moderna, said in the announcement. “Given the increased morbidity and mortality of COVID-19 in older and elderly adults, these data give us optimism in demonstrating mRNA-1273’s protection in this population, which is being evaluated in the Phase 3 COVE study.”

In mid-September, Bancel had reportedly said the company hoped to see results by October, but a dip in the average national cases made it difficult for researchers to compare the vaccine’s success against a placebo.

The U.S. has tallied over 7.2 million cases of novel coronavirus and more than 207,000 deaths.

Fox News' Kayla Rivas contributed to this report.


 
Moderna's coronavirus vaccine won't be ready for widespread distribution until spring, CEO predicts

He reportedly predicted the vaccine wouldn't be available to the general public until sometime next spring

Just a day after President Trump said the nation was only “weeks away” from a coronavirus vaccine, the head of Moderna reportedly said his company will not be able to apply for authorization from the Food and Drug Administration (FDA) until late November at the earliest.

“November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA – assuming that the safety data is good, i.e. a vaccine is deemed safe,” Stephane Bancel, Moderna CEO, told the Financial Times on Wednesday.

He then predicted that the company would not be able to release the vaccine to the general public until sometime next spring.

“I think a late [first quarter], early [second quarter] approval, is a reasonable timeline, based on what we know from our vaccine,” he told the news outlet.

MODERNA SAYS CORONAVIRUS VACCINE BOOSTS IMMUNE SYSTEM RESPONSE IN OLDER ADULTS

The government has already struck a deal with Moderna for 100 million doses of the vaccine as part of Operation Warp Speed, with an option to buy an additional 400 million doses. Bancel has previously conceded that it will take more than one company to supply enough vaccines to combat the coronavirus.

The timeline regarding a coronavirus vaccine was a hot topic of debate on Tuesday night, as Trump and former Vice President Joe Biden sparred safety concerns of a rushed vaccine and over the White House’s response to the ongoing pandemic.

TRACES OF CORONAVIRUS FOUND IN LAKE SUPERIOR WATER, RESEARCHERS SAY

“I’ve spoken to the companies and we can have it a lot sooner… I’ve spoken to Pfizer, I’ve spoken to all of the people that you have to speak to – Moderna, Johnson & Johnson, and others,” Trump said during the debate, regarding a vaccine timeline. “They can go faster than that by a lot.”

On Tuesday, Moderna announced that its vaccine candidate, dubbed mRNA-1273, elicited immune responses in older adults from a Phase 1 study in levels comparable to those seen in younger adults.

“These interim Phase 1 data suggests that mRNA-1273, our vaccine candidate for the prevention of COVID-19, can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults,” Dr. Tal Zaks, chief medical officer of Moderna, said in the announcement. “Given the increased morbidity and mortality of COVID-19 in older and elderly adults, these data give us optimism in demonstrating mRNA-1273’s protection in this population, which is being evaluated in the Phase 3 COVE study.”

In mid-September, Bancel had reportedly said the company hoped to see results by October, but a dip in the average national cases made it difficult for researchers to compare the vaccine’s success against a placebo.

The U.S. has tallied over 7.2 million cases of novel coronavirus and more than 207,000 deaths.

Fox News' Kayla Rivas contributed to this report.



 
Moderna's coronavirus vaccine won't be ready for widespread distribution until spring, CEO predicts

He reportedly predicted the vaccine wouldn't be available to the general public until sometime next spring

Just a day after President Trump said the nation was only “weeks away” from a coronavirus vaccine, the head of Moderna reportedly said his company will not be able to apply for authorization from the Food and Drug Administration (FDA) until late November at the earliest.

“November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA – assuming that the safety data is good, i.e. a vaccine is deemed safe,” Stephane Bancel, Moderna CEO, told the Financial Times on Wednesday.

He then predicted that the company would not be able to release the vaccine to the general public until sometime next spring.

“I think a late [first quarter], early [second quarter] approval, is a reasonable timeline, based on what we know from our vaccine,” he told the news outlet.

MODERNA SAYS CORONAVIRUS VACCINE BOOSTS IMMUNE SYSTEM RESPONSE IN OLDER ADULTS

The government has already struck a deal with Moderna for 100 million doses of the vaccine as part of Operation Warp Speed, with an option to buy an additional 400 million doses. Bancel has previously conceded that it will take more than one company to supply enough vaccines to combat the coronavirus.

The timeline regarding a coronavirus vaccine was a hot topic of debate on Tuesday night, as Trump and former Vice President Joe Biden sparred safety concerns of a rushed vaccine and over the White House’s response to the ongoing pandemic.

TRACES OF CORONAVIRUS FOUND IN LAKE SUPERIOR WATER, RESEARCHERS SAY

“I’ve spoken to the companies and we can have it a lot sooner… I’ve spoken to Pfizer, I’ve spoken to all of the people that you have to speak to – Moderna, Johnson & Johnson, and others,” Trump said during the debate, regarding a vaccine timeline. “They can go faster than that by a lot.”

On Tuesday, Moderna announced that its vaccine candidate, dubbed mRNA-1273, elicited immune responses in older adults from a Phase 1 study in levels comparable to those seen in younger adults.

“These interim Phase 1 data suggests that mRNA-1273, our vaccine candidate for the prevention of COVID-19, can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults,” Dr. Tal Zaks, chief medical officer of Moderna, said in the announcement. “Given the increased morbidity and mortality of COVID-19 in older and elderly adults, these data give us optimism in demonstrating mRNA-1273’s protection in this population, which is being evaluated in the Phase 3 COVE study.”

In mid-September, Bancel had reportedly said the company hoped to see results by October, but a dip in the average national cases made it difficult for researchers to compare the vaccine’s success against a placebo.

The U.S. has tallied over 7.2 million cases of novel coronavirus and more than 207,000 deaths.

Fox News' Kayla Rivas contributed to this report.


好像加国向这公司订购了疫苗
 
10 hr 30 min ago
Covid-19 vaccine for limited use likely released under EUA by end of December, disease tracker predicts
From CNN Health’s Shelby Lin Erdman

A lab technician sorts blood samples inside a lab for a Covid-19 vaccine study at the Research Centers of America in Hollywood, Florida, on August 13.

A lab technician sorts blood samples inside a lab for a Covid-19 vaccine study at the Research Centers of America in Hollywood, Florida, on August 13. Chandan Khanna/AFP/Getty Images

A Covid-19 vaccine for specific groups will likely be available by the end of December, Marc Lipsitch, a professor of epidemiology at the Harvard T.H. Chan School of Public Health, predicted Wednesday.
“So, my guess is there's a probability that a vaccine will be released by EUA (emergency use authorization) by the end of the year for, for specific groups,” Lipsitch said during a coronavirus town hall hosted by the American Lung Association.
“Otherwise, I think in terms of a fully licensed vaccine, that is more likely in the late winter, spring of 2021,” he said.
Other health experts, including Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, have also said they believe a coronavirus shot could be available for the most vulnerable populations, including health care workers, the elderly and those with underlying health conditions, by the end of the year.

There are 10 vaccines in late-stage clinical trials: Lipsitch believes the vaccine that has the best chances of crossing the finish line first is the one by pharmaceutical giant Pfizer with its partner BioNTech.

“So, the trials we’ve been hearing about, probably the two most prominent things we’ve been hearing a lot about are the two messenger RNA vaccines,” Lipsitch said.

“This is a new technology that's being used that’s being applied by both the company Moderna and the company Pfizer,” he said. “Those are both well into their Phase 3 trials and it looks like probably the Pfizer one would be the first to give an early answer about preliminary estimates of how well it works.”
Currently there are 10 Covid-19 vaccine candidates in late-stage, large clinical trials around the world.
 
21 min ago
China officially joins COVAX vaccine initiative
From CNN’s Steven Jiang in Beijing and CNN Health’s Shelby Erdman

China has signed an agreement officially joining the COVAX initiative led by the World Health Organization, which aims to provide worldwide access to effective Covid-19 vaccines.
“This is an important step China has taken to uphold the concept of a shared community of health for all and to honor its commitment to turn COVID-19 vaccines into a global public good,” China’s Ministry of Foreign Affairs spokesperson Hua Chunying said on Friday.
“We are taking this concrete step to ensure equitable distribution of vaccines, especially to developing countries, and hope more capable countries will also join and support COVAX. China will also strengthen vaccine cooperation with relevant countries through the COVAX network,” she added.
Through the COVAX Facility coordinated by Gavi, the Vaccine Alliance, more than 75 ‘high-income’ countries have committed funding to provide at least part of the cost for procuring the vaccine for poorer nations.

The United States -- which has severed its relationship with the WHO -- and Russia have not joined the program. Australia, Canada, Japan, the United Kingdom and 27 countries represented by the European Commission are members.
 
34 min ago
AstraZeneca clinical trial still paused, but HHS says there could be new information soon
From CNN's Amanda Watts and Maggie Fox

A sign featuring the AstraZeneca logo stands at the company's DaVinci building at the Melbourn Science Park in Cambridge, U.K., on June 8.

A sign featuring the AstraZeneca logo stands at the company's DaVinci building at the Melbourn Science Park in Cambridge, U.K., on June 8. Jason Alden/Bloomberg/Getty Images

The hold placed on the AstraZeneca coronavirus vaccine clinical trial continues, Paul Mango, deputy chief of staff for policy at the US Department of Health Human Services said during a briefing on Friday.

“That moratorium persists,” he said. “FDA continues to review safety information, and we'll just have to see over the next week or so where that turns out.”
Four of the six candidates for a vaccine are currently in Phase three clinical trails, he said. One of those is the paused AstraZeneca trial.

“The other three are doing exceptionally well,” Mango said, adding that minority recruiting has “exceeded the threshold necessary to ensure we have the appropriate diversity.”

“Both Moderna and Pfizer – as you've read – are essentially completed with their recruiting into their clinical trials,” Mango said.

“In Johnson and Johnson, the Janssen product, really just started just in the last couple of weeks. And just by way of reminder, again, that's a single dose vaccine, not two doses, so we anticipate that they'll get through their clinical trials a bit faster than the other two,” he added.

Some background: AstraZeneca announced last month that it had paused global trials of its coronavirus vaccine because of an unexplained illness in one of the volunteers.

"As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process triggered a pause to vaccination to allow review of safety data," the company said in a statement sent to CNN.

National Institutes of Health director Dr. Francis Collins told a Senate hearing that it's a standard precaution in vaccine trials meant to ensure experimental vaccines don't cause serious reactions among participants.

"To have a clinical hold, as has been placed on AstraZeneca, as of yesterday, because of a single serious adverse event, is not at all unprecedented," Collins said at a hearing of the Senate Heath, Education, Labor and Pensions committee.

The company is testing its vaccine, called the Oxford vaccine because it was developed with Britain's University of Oxford, in the United States as well as the UK, Latin America, Asia, Europe and Africa.
 
在中文社区,没事飙英语,还长篇裹脚布,不是找臭吗?:kan:

有本事自己写,要不讲讲莎士比亚,烦 :monster:
 
18 min ago
China is doubling down in the global push for a coronavirus vaccine
From CNN's Nectar Gan

The global push to develop a coronavirus vaccine is gathering pace, but much to the likely frustration of US President Donald Trump, caution exercised by American drug makers and regulators has put China out in front ... for now.

Moderna, a leading coronavirus vaccine maker, said this month it will not be ready to apply for emergency use authorization until at least November 25. Meanwhile, the US-based trial sites of another frontrunner, AstraZeneca, have placed testing on hold after a participant in Britain developed a serious illness last month, further undermining Trump's hopes that a vaccine would be ready in time for Election Day on November 3.

The stringent US safety protocols have shifted the so-called vaccine race in China's favor, where -- for better or worse -- political will holds a much larger sway over state, commercial and individual actions, potentially bending rules or norms as needed.

China's leader Xi Jinping has repeatedly urged the country's scientists to accelerate the research and development of coronavirus vaccines. Chinese drug makers have also been told to treat their work as an "important political task" -- and they are doing everything they can to follow that directive.

While the successful development of a vaccine would not preclude other countries from continuing to pursue their own research, China has placed special emphasis on being first.

Read more here:

China doubles down in push for coronavirus vaccine

RELATED
China doubles down in push for coronavirus vaccine
 
后退
顶部